Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research[1][2].

Triglycidyl isocyanurate (0-30 μM; 48?hours) reduces the growth of spheroids of human non-small-cell-lung cancer cells in culture, it leads to a gradual reduction in size for tumorspheres of A549, H460 and H1299 cells[1].Triglycidyl isocyanurate (0-30 μM; 48?hours) inhibits expression of akt1/2/3 and phosphorylated Aktser473/474/472 of A549, H460 and H1299 tumorspheres, however, the cleavage of PARP and procaspase-3 plus the emergent active caspase-3 fragment are only visible in H460 and A549 tumorspheres[1]. Cell Viability Assay[1] Cell Line: A549, H460 and H1299 cells

Triglycidyl isocyanurate (subcutaneous injection; 1.8 and 3.6 mg/kg; every 2-3 days for total seven times; 30 days) suppresses the growth of xenograft tumors and has no effects on weight in nude mice[2]. Animal Model: Female nu/nu mice with Huh7 cells subcutaneously injected into the dorsal area[2]

[1]. Yu-Ling Ni, et al. Teroxirone motivates apoptotic death in tumorspheres of human lung cancer cells. Chem Biol Interact. 2018 Aug 1;291:137-143 [2]. Seung-Hun Kim, et al. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells.Biomed Pharmacother. 2018 Mar;99:997-1008